Safety and Efficacy of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes Mellitus. [clinicaltrials:NCT00063128]

Bio2RDF identifier

NCT00063128

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00063128

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00063128

actual enrollment [clinicaltrials_vocabulary:actual-enrollment]

119

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT00063128 arm group 7fc56270e7a70fa81a5935b72eacbe29 [clinicaltrials_resource:NCT00063128/arm-group/7fc56270e7a70fa81a5935b72eacbe29]

NCT00063128 arm group 9d5ed678fe57bcca610140957afab571 [clinicaltrials_resource:NCT00063128/arm-group/9d5ed678fe57bcca610140957afab571]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:d942c8692d257084abf3ac87279faff6

brief summary [clinicaltrials_vocabulary:brief-summary]

This is a research stud ...... ng a special handheld device.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Safety and Efficacy of Human I ...... With Type 1 Diabetes Mellitus.

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

test the hypothesis that preprandial HIIP plus insulin glargine is noninferior to preprandial injectable insulin (regular human insulin or insulin lispro) plus insulin glargine with respect to HbA1c 12 weeks per therapy [clinicaltrials_resource:bf2d491918381aa9c00489bda42e7b75]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

test the hypothesis that preprandial HIIP plus insulin glargine is noninferior to preprandial injectable insulin (regular human insulin or insulin lispro) plus insulin glargine with respect to HbA1c 12 weeks per therapy [clinicaltrials_resource:1b92bf7ab7e7e554e5604a1748afeacb]

test the hypothesis that preprandial HIIP plus insulin glargine is noninferior to preprandial injectable insulin (regular human insulin or insulin lispro) plus insulin glargine with respect to HbA1c 12 weeks per therapy [clinicaltrials_resource:1cd434971b2bf51872f079852a417c01]

test the hypothesis that preprandial HIIP plus insulin glargine is noninferior to preprandial injectable insulin (regular human insulin or insulin lispro) plus insulin glargine with respect to HbA1c 12 weeks per therapy [clinicaltrials_resource:3bda528731485d3555ee3ac7ce66883e]

test the hypothesis that preprandial HIIP plus insulin glargine is noninferior to preprandial injectable insulin (regular human insulin or insulin lispro) plus insulin glargine with respect to HbA1c 12 weeks per therapy [clinicaltrials_resource:4674b3efe7f83a53d17ccb447cecbb63]

test the hypothesis that preprandial HIIP plus insulin glargine is noninferior to preprandial injectable insulin (regular human insulin or insulin lispro) plus insulin glargine with respect to HbA1c 12 weeks per therapy [clinicaltrials_resource:4e37980bcae2c69a3ef0140641731626]

test the hypothesis that preprandial HIIP plus insulin glargine is noninferior to preprandial injectable insulin (regular human insulin or insulin lispro) plus insulin glargine with respect to HbA1c 12 weeks per therapy [clinicaltrials_resource:8b181b2b72c702ce305e2058acc0bc5e]

test the hypothesis that preprandial HIIP plus insulin glargine is noninferior to preprandial injectable insulin (regular human insulin or insulin lispro) plus insulin glargine with respect to HbA1c 12 weeks per therapy [clinicaltrials_resource:9413a3b5b9f427c08dc62172edf5d7fd]

test the hypothesis that preprandial HIIP plus insulin glargine is noninferior to preprandial injectable insulin (regular human insulin or insulin lispro) plus insulin glargine with respect to HbA1c 12 weeks per therapy [clinicaltrials_resource:e5fd68df59718c4afb3fa1a94c523881]

collaborator [clinicaltrials_vocabulary:collaborator]

Eli Lilly and Company [clinicaltrials_resource:7842d4a3c63f3eec2ded513ced2c398f]

completion date [clinicaltrials_vocabulary:completion-date]

2004-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00063128 [clinicaltrials_resource:6dff146ff46b72e76d4df399d1be41f3]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2003-06-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

intervention [clinicaltrials_vocabulary:intervention]

human insulin inhalation powder (HIIP) [clinicaltrials_resource:d3f8e6f1d0b98f1b4c5d2f816d5b7962]

insulin [clinicaltrials_resource:f5fc73e26444b9351b0057a1fc4ae84b]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Insulin [clinicaltrials_resource:38ef854e1e2fa47e4184cccf82611e61]

Insulin, Globin Zinc [clinicaltrials_resource:cfe6e68d4b07bb03d3e7b7e9860f0023]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

Yes

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2007-12-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Eli Lilly and Company [clinicaltrials_resource:7842d4a3c63f3eec2ded513ced2c398f]

link [clinicaltrials_vocabulary:link]

Lilly Clinical Trial Registry [clinicaltrials_resource:83adce4c7f71cdc37c40acbca0949b69]

location [clinicaltrials_vocabulary:location]

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. [clinicaltrials_resource:e3f338c97370e0e993f58dbf5525db1f]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00063128

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

2

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

Safety and Efficacy of Human I ...... With Type 1 Diabetes Mellitus

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

6,944

http://www.w3.org/2001/XMLSchema#integer

overall official [clinicaltrials_vocabulary:overall-official]

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) [clinicaltrials_resource:c3a080b6fd8247f9005cdd94428c8a66]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:965595316c5ae1a4521a298d475eb908]

phase [clinicaltrials_vocabulary:phase]

Phase 2 [clinicaltrials_resource:56e0338b27a2d68f77402c88327b3f8d]

responsible party [clinicaltrials_vocabulary:responsible-party]

Chief Medical Officer, Eli Lilly [clinicaltrials_resource:e579eaccf1c6bffa5de03476e056317b]

secondary id [clinicaltrials_vocabulary:secondary-id]

H7U-MC-IDAI

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

Eli Lilly and Company [clinicaltrials_resource:7842d4a3c63f3eec2ded513ced2c398f]

start date [clinicaltrials_vocabulary:start-date]

2003-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00063128 study design [clinicaltrials_resource:7f81b54a8c7847651b859eb374a99a1e]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00063128

verification date [clinicaltrials_vocabulary:verification-date]

2007-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00063128

http://www.w3.org/2001/XMLSchema#string

title

Safety and Efficacy of Human I ...... With Type 1 Diabetes Mellitus.

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Safety and Efficacy of Human I ...... . [clinicaltrials:NCT00063128]

@en